Trials / Completed
CompletedNCT00093080
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ridaforolimus | 12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2004-10-04
- Last updated
- 2015-02-13
Source: ClinicalTrials.gov record NCT00093080. Inclusion in this directory is not an endorsement.